teaser
The provisional meeting schedule is online now, including keynote and session themes:
Programme:
- New immune checkpoints as drug targets
- Phase 1 studies, completed or in progress
- Whole-genome sequencing in early-phase development
- Metabolic targets
- Immunoconjugates for cancer therapy
- Emerging new drugs and targets in hemato-oncology
- Drugs targeting the RAS/RAF/MEK pathway
- Preclinical models in drug discovery and development
A new element is the special biotech event, which will feature biotechs’ innovations in oncology. It will provide delegates a great view of the innovations (small) biotech companies are bringing to cancer patient management It will offer excellent business-to-business networking opportunities between biotech companies and academic investigators as well as biotech and pharma representatives.
www.tatcongress.org/progr-tat13.html
